HSD17B13 and metabolic dysfunction-associated steatotic liver disease: Notably, lower HSD17B13 expression induced by the injection of AAV8-shHsd17b13 improved the characteristics of NAFLD induced by HFD remarkably, including hepatocyte steatosis and fibrosis (Figure 7E,F), and the outcomes were associated with the decreased HSC activation (Figure 7G) and the expression of proteins associated with lipid metabolisms (Figure 7H).